1. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Issue 4 (April 2017) Authors: Ladenstein, Ruth; Pötschger, Ulrike; Pearson, Andrew D J; Brock, Penelope; Luksch, Roberto; Castel, Victoria; Yaniv, Isaac; Papadakis, Vassilios; Laureys, Geneviève; Malis, Josef; Balwierz, Walentyna; Ruud, Ellen; Kogner, Per; Schroeder, Henrik; de Lacerda, Ana Forjaz; Beck-Popovic, Maja; Bician,... Journal: Lancet oncology Issue: Volume 18:Issue 4(2017:Apr.) Page Start: 500 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. (5th March 2018) Authors: Depuydt, Pauline; Boeva, Valentina; Hocking, Toby D; Cannoodt, Robrecht; Ambros, Inge M; Ambros, Peter F; Asgharzadeh, Shahab; Attiyeh, Edward F; Combaret, Valérie; Defferrari, Raffaella; Fischer, Matthias; Hero, Barbara; Hogarty, Michael D; Irwin, Meredith S; Koster, Jan; Kreissman, Susan; Laden... Journal: Journal of the National Cancer Institute Issue: Volume 110:Number 10(2018) Page Start: 1084 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗